COVID-19 Updates

Visit UC San Diego's Coronavirus portal for the latest information for the campus community.

Mell Lab News

AUGUST 2019

Collaboration with NRG Oncology produces novel predictive nomogram

ALT TEXT HERE

In August, we published the first study showing that the benefit of intensive cancer therapy depends on the proportional event risk attributable to cancer (omega score), in line with previous theoretical studies. The study implemented a novel methodology called generalized competing event (GCE) modeling. The method is being incorporated into the design of ongoing clinical trials, applying personalized medicine to select optimal treatment approaches for cancer. The nomogram is published on comogram.org.

Reference:

Mell LK, Shen H, Nguyen-Tan PF, Rosenthal DI, Zakeri K, Vitzthum LK, Frank SJ, Schiff PB, Trotti A, Bonner JA, Jones CU, Yom SS, Thorstad WL, Wong S, Shenouda G, Ridge JA, Zhang QE, Le QT. Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer. Clin Cancer Res. 2019 Aug 16. doi: 10.1158/1078-0432.CCR-19-1832. PMID: 31420360.

 

Learn More

SEPTEMBER 2019

Promising Phase I KEYCHAIN results presented at ASTRO

The KEYCHAIN trial is the first study to compare radiation therapy with concurrent pembrolizumab, a PD-1 inhibitor, against standard chemoradiotherapy for intermediate risk P16-positive head and neck cancer. We established the safety and preliminary efficacy of this approach in a Phase I lead-in trial, presented this month at the 61st annual ASTRO meeting in Chicago, IL. The randomized trial is being conducted in collaboration with Washington University, Yale University, Moffitt Cancer Center, University of Arizona, and University of Cincinnati.

Reference:

Sacco AG, Sharabi AN, Jing Z, Pittman E, Gold KA, Sumner W, Califano JA, Brumund KT, Orosco R, Rash D, Coffey CS, Cohen EEW, Mell LK. Radiotherapy with concurrent and adjuvant pembrolizumab in patients with P16-Positive locoregionally advanced head and neck cancer: KEYCHAIN trial lead-in results (abstr.) Int J Radiat Oncol Biol Phys 2019; 105(1):E363-4.

 

Learn More
ALT TEXT HERE